[{"id":"37ba8d01-7c78-43cc-81e1-59e78827f9d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04367675","created_at":"2021-01-18T21:06:34.302Z","updated_at":"2024-07-02T16:35:32.189Z","phase":"Phase 1b","brief_title":"INO 5401 Vaccination in BRCA1/2 Mutation Carriers","source_id_and_acronym":"NCT04367675","lead_sponsor":"University of Pennsylvania","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e INO-5401 • rocakinogene sifuplasmid (INO-9012)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 04/20/2021","start_date":" 04/20/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-10-23"},{"id":"65549955-d067-4c21-bc42-ff091226f6d2","acronym":"UV1-103","url":"https://clinicaltrials.gov/study/NCT03538314","created_at":"2021-01-18T17:26:03.967Z","updated_at":"2024-07-02T16:36:00.254Z","phase":"Phase 1","brief_title":"UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma","source_id_and_acronym":"NCT03538314 - UV1-103","lead_sponsor":"Ultimovacs ASA","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • UV1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/09/2018","start_date":" 07/09/2018","primary_txt":" Primary completion: 10/01/2022","primary_completion_date":" 10/01/2022","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2022-11-17"},{"id":"4823acf0-a35f-46e1-8e02-1a70ad0be285","acronym":"FOCUS","url":"https://clinicaltrials.gov/study/NCT05075122","created_at":"2021-10-12T14:53:00.645Z","updated_at":"2024-07-02T16:36:15.736Z","phase":"Phase 2","brief_title":"Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab","source_id_and_acronym":"NCT05075122 - FOCUS","lead_sponsor":"Martin-Luther-Universität Halle-Wittenberg","biomarkers":" PD-L1 • IFNG","pipe":"","alterations":" ","tags":["PD-L1 • IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Leukine (sargramostim) • UV1"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 08/02/2021","start_date":" 08/02/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2022-03-09"},{"id":"73c201a6-e02a-4259-b6f1-d64c285f2a0c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02301754","created_at":"2021-01-18T10:52:53.377Z","updated_at":"2024-07-02T16:37:02.457Z","phase":"Phase 1","brief_title":"INVAC-1 Anti-Cancer hTERT DNA Immunotherapy","source_id_and_acronym":"NCT02301754","lead_sponsor":"Invectys","biomarkers":" IFNG • IL6 • TNFA • CXCL8 • IL1B","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • CXCL8 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e INVAC-1"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 02/01/2018","primary_completion_date":" 02/01/2018","study_txt":" Completion: 06/01/2018","study_completion_date":" 06/01/2018","last_update_posted":"2019-02-26"},{"id":"13f962ad-4e51-40e4-943d-c2f1a42f8f88","acronym":"","url":"https://clinicaltrials.gov/study/NCT02327468","created_at":"2021-01-18T11:02:43.451Z","updated_at":"2024-07-02T16:37:16.072Z","phase":"Phase 1","brief_title":"Inovio TRT-001: Telomerase DNA Immunotherapy in Breast, Lung, and Pancreatic Cancers","source_id_and_acronym":"NCT02327468","lead_sponsor":"Inovio Pharmaceuticals","biomarkers":" PGR • CD8 • PTPRC • FOXP3","pipe":" | ","alterations":" HER-2 negative","tags":["PGR • CD8 • PTPRC • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e rocakinogene sifuplasmid (INO-9012) • INO-1400"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 12/01/2014","start_date":" 12/01/2014","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 04/01/2018","study_completion_date":" 04/01/2018","last_update_posted":"2017-11-24"}]